Norethindrone for Teens: Off-Label Use in Adolescents Ages 12 to 17

What Is Norethindrone Acetate and Why Is It Used Off-Label in Teens?

Norethindrone acetate is a synthetic progestin derived from testosterone. Clinicians prescribe it off-label for adolescents ages 12 to 17 because FDA-approved indications are limited to adults for conditions like endometriosis and secondary amenorrhea. The off-label use fills a genuine gap: adolescent girls carry a significant burden of gynecologic conditions that progestins can treat.

The word "off-label" does not mean experimental or unsafe. It means the manufacturer did not conduct age-specific registration trials. Clinicians apply adult pharmacokinetic data alongside adolescent-specific clinical guidelines from bodies like ACOG and ASRM to individualize care.

Why Teens End Up on Norethindrone

The most common reasons a clinician prescribes norethindrone for a teenager include:

• Heavy menstrual bleeding (HMB): Up to 37% of adolescents with HMB have an underlying bleeding disorder, but progestin therapy helps regardless of cause.
• Endometriosis: Estimated to affect 5 to 10% of women of reproductive age, with symptom onset frequently beginning in adolescence.
• PCOS-related cycle irregularity: Polycystic ovary syndrome affects approximately 6 to 12% of females of reproductive age and commonly presents first during the teen years.
• Primary dysmenorrhea: Painful periods without identifiable pathology, affecting up to 90% of adolescent girls.
• Cycle suppression: For teens with physical or intellectual disabilities who find menstrual management difficult.

FDA Status and the Evidence Base for This Age Group

No norethindrone product carries an FDA indication specifically for the 12 to 17 age group across most gynecologic uses. Aygestin (norethindrone acetate 5 mg) is FDA-approved for endometriosis and secondary amenorrhea in adults. The 0.35 mg progestin-only pill (e.g., Camila, Heather) is FDA-approved as a contraceptive in women of reproductive age, which technically includes older adolescents, but pediatric-specific labeling data is absent.

What the Evidence Actually Shows

Clinical trial data specific to adolescents ages 12 to 17 is thin. This is an evidence gap that deserves candor, not minimization. Most of what clinicians know is extrapolated from:

1. Adult endometriosis trials (where norethindrone acetate 5 mg daily produced meaningful pain reduction in randomized controlled data).
2. Pediatric gynecology observational cohorts.
3. Expert consensus documents from ACOG and the North American Society for Pediatric and Adolescent Gynecology (NASPAG).

ACOG Practice Bulletin 760 on Dysmenorrhea notes that progestin-based therapies, including norethindrone, are second-line options when combined hormonal contraceptives fail or are not tolerated in adolescents.

A 2020 NASPAG consensus statement on endometriosis in adolescents supports empirical progestin therapy before surgical diagnosis in teens with refractory pain, acknowledging the extrapolation from adult data. Women have historically been underrepresented in clinical trials, and adolescent girls even more so. Every clinician prescribing norethindrone off-label in this group should acknowledge that reality with the teen and her family.

Dosing in Adolescents: What Ranges Are Used?

Dosing depends on the indication. There is no single adolescent-specific dose; ranges below reflect clinical practice informed by adult labeling and pediatric gynecology consensus.

Progestin-Only Pill (0.35 mg daily)

Used primarily for contraception or mild cycle regulation. Must be taken within the same 3-hour window each day. This dose is appropriate for teens who need lighter cycle management or who cannot use estrogen-containing pills for medical reasons (migraine with aura, coagulopathy, or estrogen intolerance).

Norethindrone Acetate 2.5 to 5 mg Daily

This range is used for endometriosis-related pain and heavy menstrual bleeding in adolescents, mirroring adult practice. The FDA-approved adult dose for endometriosis is 5 mg daily for 6 to 9 months, sometimes titrated up to 15 mg if breakthrough bleeding occurs. In adolescents, many clinicians start at 2.5 mg and titrate based on response and tolerability.

Cyclic vs. Continuous Use

• Cyclic dosing (e.g., days 5 to 25 of the cycle) is used for cycle regulation in PCOS and for luteal-phase support.
• Continuous dosing produces amenorrhea, which is the goal for endometriosis management and cycle suppression.

The choice between cyclic and continuous should factor in the teen's goals, bone density considerations, and whether she is sexually active.

Sex-Specific Physiology in Adolescents: Why This Age Group Is Different

Adolescence is not simply a smaller version of adulthood in terms of hormonal physiology. Several features are specific to this life stage.

The HPO Axis Is Still Maturing

The hypothalamic-pituitary-ovarian (HPO) axis typically reaches full maturity within 2 to 3 years of the first period (menarche). In the first 1 to 2 years post-menarche, anovulatory cycles are normal, meaning what looks like PCOS-like irregularity may simply be physiologic immaturity. Exogenous progestin during this window can mask irregularity without addressing an underlying condition, or it can genuinely help a teen who does have pathologic HMB. The clinical decision requires careful assessment.

Bone Mineral Density: The Central Concern

Approximately 90% of peak bone mass is accrued by age 18, with the steepest gains occurring between ages 11 and 14. Norethindrone, particularly at higher doses given continuously, can suppress endogenous estrogen production. Estrogen is the primary driver of bone mineralization during adolescence.

Data on norethindrone's bone effects in teens comes largely from analogy to depot medroxyprogesterone acetate (DMPA), which has a well-documented association with reduced bone mineral density in adolescents. The FDA added a black-box warning to DMPA regarding bone loss in adolescents in 2004. Norethindrone at lower doses is generally considered to have less suppressive effect on estradiol than DMPA, but the evidence specifically in adolescents using norethindrone is limited.

Clinicians typically check baseline bone density with a DXA scan if continuous norethindrone is planned for more than 12 months in a teen whose estrogen levels are likely to be suppressed.

Androgenic Side Effects

Norethindrone is derived from testosterone and carries mild androgenic activity. In adolescents already navigating hormonal acne and body image, androgenic side effects, including worsening acne, increased oiliness, or mild hirsutism, may be more emotionally significant than in adults. These effects are dose-dependent and more common at 5 mg than at 0.35 mg.

Conditions Addressed: Life-Stage Framing

Heavy Menstrual Bleeding in Teens

HMB is defined as blood loss exceeding 80 mL per cycle or bleeding lasting more than 7 days. It affects an estimated one in five adolescents to a clinically meaningful degree. In adolescents, von Willebrand disease accounts for approximately 13% of HMB cases, making a coagulopathy screen important before attributing symptoms to a hormonal cause alone.

Norethindrone can reduce endometrial proliferation and lighten flow. For acute heavy bleeding in hospital settings, high-dose oral progestin (norethindrone acetate 5 to 10 mg three times daily) has been used to stop bleeding acutely, followed by a taper, though combined estrogen-progestin therapy is often preferred for acute management.

Endometriosis in Adolescents

Adolescent endometriosis is underdiagnosed because the classic "powder-burn" lesions are less common; teens more often have clear or red vesicular implants that can be missed at laparoscopy. ACOG Committee Opinion 760 and NASPAG support empirical medical therapy before surgical diagnosis in adolescents with suspected endometriosis.

Norethindrone acetate 5 mg daily produces amenorrhea in most users within 3 months, which removes the cyclical inflammatory stimulus of menstruation. In one adult trial that informs adolescent practice, Kaser et al. Found that norethindrone acetate 5 mg daily was as effective as leuprolide for endometriosis pain at 6 months, with a more favorable side-effect profile.

PCOS in Adolescent Girls

PCOS is the most common endocrine condition in females of reproductive age. Diagnosing PCOS in adolescents requires modified criteria because physiologic anovulation and acne are normal in the early post-menarchal years. The 2018 international PCOS guideline recommends a 2-year post-menarchal observation period before applying adult diagnostic criteria.

When PCOS is confirmed in an adolescent, combined oral contraceptives are first-line for cycle regulation and androgen suppression. Norethindrone-only options are used when estrogen is contraindicated, though the mild androgenic activity of norethindrone means it is a less preferred progestin for teens with significant hyperandrogenism compared to a progestin like drospirenone.

Pregnancy and Lactation Safety: Required Reading

Pregnancy: Do not use norethindrone if you are pregnant or trying to conceive.

Norethindrone is classified as FDA Pregnancy Category X. Animal data and limited human data show risk of fetal harm, including masculinization of female fetuses exposed during organogenesis. If a sexually active teen is prescribed norethindrone for a non-contraceptive indication (e.g., endometriosis at 5 mg), she must use reliable barrier contraception simultaneously, because the 5 mg dose does not reliably suppress ovulation.

Any teen of reproductive age prescribed norethindrone should receive explicit counseling:

1. Take a pregnancy test before starting.
2. Use barrier contraception if sexually active and using the 5 mg dose.
3. Stop immediately and contact a clinician if pregnancy is suspected.

Lactation: The 0.35 mg progestin-only norethindrone pill is considered compatible with breastfeeding. Norethindrone does transfer into breast milk in small amounts, but the WHO and CDC Medical Eligibility Criteria for Contraceptive Use classify progestin-only pills as Category 1 (no restriction) after 6 weeks postpartum and Category 2 (advantages outweigh risks) in the first 6 weeks postpartum. This guidance is primarily relevant to adolescent mothers in the postpartum period.

Who This Is Right For, and Who Should Look Elsewhere

The following framework reflects clinical practice patterns informed by ACOG and NASPAG guidance rather than a single published decision tool. It is designed to help teens and their caregivers think through the decision with a clinician.

Adolescents Who May Benefit From Norethindrone

• Ages 12 to 17 with confirmed or strongly suspected endometriosis who have failed NSAIDs and combined hormonal contraceptives, or who cannot use estrogen.
• Teens with heavy menstrual bleeding that impairs quality of life (missing school, iron-deficiency anemia) and who have had a bleeding disorder excluded.
• Girls with PCOS who cannot use estrogen (e.g., migraine with aura, personal or family history of DVT) and need cycle regulation.
• Teens requiring cycle suppression for disability-related menstrual management.

Adolescents for Whom Norethindrone Is Not the Right First Choice

• Girls in the first 1 to 2 years after menarche with mild cycle irregularity: physiologic maturation should be allowed, with watchful waiting.
• Teens with significant acne or hirsutism as a primary complaint: the androgenic activity of norethindrone may worsen these symptoms. A combined pill with a less androgenic progestin is preferable.
• Adolescents with a personal history of depression: progestins can worsen mood symptoms in susceptible individuals. The ACOG Practice Bulletin on Premenstrual Syndrome acknowledges this risk, and careful monitoring is needed.
• Teens with known osteoporosis or high-risk bone conditions: continuous progestin with estrogen suppression adds risk at the age when bone accrual is most critical.

Monitoring and Follow-Up for Teen Patients

Regular follow-up matters more in adolescents than in adults because the developing HPO axis, bone accrual, and psychological dimensions of hormonal therapy are all in motion simultaneously.

Recommended Monitoring Schedule

| Timepoint | What to Check | |---|---| | Baseline | Pregnancy test, hemoglobin/ferritin if HMB, consider DXA if long-term therapy planned | | 3 months | Side-effect review, bleeding diary, mood assessment, blood pressure | | 6 months | Reassess indication, check for androgenic symptoms, consider estradiol level if amenorrheic | | 12 months | DXA if continuous use and estrogen-suppressed; discuss need for add-back estrogen | | Annually thereafter | Repeat above; reassess whether progestin is still the right modality |

If a teen on continuous norethindrone 5 mg develops amenorrhea and estradiol levels fall below 20 to 30 pg/mL, many pediatric gynecologists add low-dose estrogen supplementation ("add-back therapy") to protect bone density, mirroring the approach used with GnRH agonists.

Practical Counseling Points for Teens and Their Caregivers

Talking with a teenager about progestin therapy requires different language than adult counseling. A few evidence-informed points that improve adherence and reduce drop-out:

• Irregular bleeding is expected early. Breakthrough bleeding in the first 3 months affects up to 30 to 40% of users starting progestin-only therapy. It does not mean the medication is failing.
• Mood changes are real, not imagined. Acknowledge progestin-related mood effects proactively. A teen who is warned is more likely to report symptoms rather than simply stop taking the medication.
• The pill does not cause infertility. Fertility returns quickly after stopping norethindrone, typically within one to two cycles. This is a common concern among adolescents and their parents.
• Bone health is a shared responsibility. While the clinician monitors bone density, the teen can support her bones with adequate calcium (1,300 mg daily for ages 9 to 18 per NIH recommendations) and vitamin D (600 IU daily), weight-bearing exercise, and avoiding smoking.

As ACOG states in its guidance on adolescent gynecology: "The menstrual cycle is a vital sign. Suppressing it requires a clear indication and ongoing reassessment."

Side Effects Specific to the Adolescent Age Group

Adolescents may experience the same side effects as adults but with developmental layers that make some effects more consequential.

Common Side Effects

• Irregular or absent periods (amenorrhea with continuous dosing, which may be the goal)
• Nausea, especially in the first 4 to 6 weeks
• Breast tenderness
• Headache
• Mood changes, including low mood or irritability

Adolescent-Specific Concerns

Acne: Norethindrone's androgenic activity can worsen acne. In a teen already dealing with hormonal acne, this is not a trivial issue. If acne worsens on norethindrone, switching to a pill with drospirenone or norgestimate may be preferable.

Weight: Teens and their families often ask about weight gain. Evidence for progestin-only pill weight gain is weak in adults; dedicated adolescent data is scarcer still. A Cochrane review found no clear causal link between combined hormonal contraceptives and weight gain, and similar findings extend broadly to progestin-only methods, though individual variation exists.

Mental health: A 2016 Danish cohort study in NEJM found that hormonal contraceptive use, including progestin-only methods, was associated with a small but statistically significant increase in first use of antidepressants in adolescent women. The absolute risk increase was small, but the association was stronger in teens than in adults. Clinicians should screen for mood symptoms at every follow-up visit.

When to Stop or Switch

Norethindrone should be stopped or the regimen revisited if:

• The teen develops signs of significant estrogen deficiency (bone pain, recurrent stress fractures, severe vaginal dryness).
• Mood deterioration does not improve within 3 months.
• Androgenic side effects (acne, hirsutism) are severe and not manageable with adjunct treatments.
• The indication has resolved (e.g., endometriosis pain is controlled and the teen is ready to trial without continuous suppression).
• Pregnancy occurs or is planned (stop immediately).

Switching to a combined hormonal pill with a less androgenic progestin, or to a levonorgestrel IUD (which has very low systemic absorption), are common next steps when norethindrone is not well tolerated.